What is the appropriate intravenous nicardipine infusion dosage for a 23 kg child?

Nicardipine IV Dosing for 23 kg Pediatric Patient

For a 23 kg child requiring IV nicardipine, start at 0.5-1 mcg/kg/min (11.5-23 mcg/min or 0.69-1.38 mg/hr), titrate to effect up to a maximum of 3-5 mcg/kg/min (69-115 mcg/min or 4.1-6.9 mg/hr), and administer through a central line or large peripheral vein, changing the site every 12 hours if using peripheral access.

Dosing Algorithm

Initial Dose

• Start at 0.5-1 mcg/kg/min based on pediatric research evidence 1, 2
• For this 23 kg patient: 11.5-23 mcg/min (0.69-1.38 mg/hr)
• Most neonatal and pediatric studies successfully initiated at 0.5-1 mcg/kg/min 1, 2

Titration Strategy

• Increase by 0.5-1 mcg/kg/min increments every 15-30 minutes until target blood pressure achieved
• Maximum maintenance dose: 3-5 mcg/kg/min (69-115 mcg/min or 4.1-6.9 mg/hr for 23 kg) 3, 4
• Blood pressure typically responds within 15 minutes in pediatric patients 3

Target Blood Pressure

• For children <4 years: systolic BP ~90 mmHg
• For children ≥5 years: systolic BP ≤110 mmHg 3
• Adjust based on clinical indication (hypertensive emergency, post-cardiac surgery, etc.)

Administration Requirements

Vascular Access

• Strongly prefer central venous access to minimize thrombophlebitis risk 5, 4
• If using peripheral IV: change site every 12 hours 6
• Two of seven patients developed superficial thrombophlebitis with peripheral administration 5

Preparation

• FDA-approved concentration: 0.1 mg/mL (dilute 25 mg vial in 240 mL compatible fluid) 6
• Pre-mixed bags available at 0.1 mg/mL and 0.2 mg/mL 6
• Compatible with D5W, NS, D5NS, D5 0.45% NS 6
• NOT compatible with sodium bicarbonate or lactated Ringer's 6

Evidence-Based Pediatric Experience

Efficacy Data

• Success rate: 99%+ in controlling hypertension across pediatric studies 3, 5, 4, 2
• Mean blood pressure reduction: 10-25% within first hour 2
• Effective in post-cardiac surgery (including coarctation repair, tetralogy of Fallot) 3
• Effective in renal hypertensive emergencies 5, 4

Safety Profile

• No hypotension or severe adverse effects reported in pediatric studies when properly titrated 3, 1, 2
• Heart rate typically unchanged at standard doses 2
• Main adverse effect: superficial thrombophlebitis with peripheral administration 5, 4

Critical Monitoring Parameters

• Blood pressure every 5-15 minutes during titration
• Heart rate continuously (watch for reflex tachycardia)
• IV site inspection every 2-4 hours for phlebitis
• Discontinue immediately if hypotension develops; effects offset within 30 minutes 6

Important Caveats

Contraindications

• Advanced aortic stenosis 6
• Do not use in small dorsal hand/wrist veins 6

Special Considerations

• Not FDA-approved for pediatric use - all dosing extrapolated from research studies and off-label experience 6
• Adult FDA dosing (5 mg/hr initial, titrate by 2.5 mg/hr) is NOT appropriate for pediatric weight-based dosing 6
• Duration of therapy in pediatric studies: typically 1-3 days (range 30-42 hours) 3, 1

Drug Interactions

• Monitor if patient on beta-blockers (nicardipine is NOT a beta-blocker and provides no protection against withdrawal) 6
• May increase cyclosporine/tacrolimus levels 6

The weight-based pediatric dosing (0.5-1 mcg/kg/min starting dose) differs substantially from adult fixed-dose recommendations and must be calculated specifically for this 23 kg patient rather than using adult protocols.